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Abstract 26 
 27 
In the emerging field of nanomedicine, targeted delivery of nanoparticle encapsulated active pharmaceutical 28 
ingredients (API) is seen as a potential significant development, promising improved pharmacokinetics and 29 
reduced side effects. In this context, understanding the cellular uptake of the nanoparticles and subsequent 30 
subcellular distribution of the API is of critical importance. Doxorubicin (DOX) was encapsulated within 31 
chitosan nanoparticles to investigate its intracellular delivery in A549 cells in vitro. Unloaded (CS-TPP) and 32 
doxorubicin-loaded (DOX-CS-TPP) chitosan nanoparticles were characterised for size (473±41 nm), 33 
polydispersity index (0.3±0.2), zeta potential (34±4 mV), drug content (76±7 µM) and encapsulation efficiency 34 
(95±1%). The cytotoxic response to DOX-CS-TPP was substantially stronger than to CS-TPP, although weaker 35 
than that of the equivalent free DOX. Fluorescence microscopy showed a dissimilar pattern of distribution of 36 
DOX within the cell, being predominantly localised in the nucleus for free form and in cytoplasm for DOX-CS-37 
TPP. Confocal microscopy demonstrated endosomal localisation of DOX-CS-TPP. Numerical simulations, 38 
based on a rate equation model to describe the uptake and distribution of the free DOX, nanoparticles and DOX 39 
loaded nanoparticles within the cells, and the subsequent dose and time dependent cytotoxic responses, were 40 
used to further elucidate the API distribution processes. The study demonstrates that encapsulation of the API in 41 
nanoparticles results in a delayed release of the drug to the cell, resulting in a delayed cellular response. This 42 
work further demonstrates the potential of mathematical modelling in combination with intracellular imaging 43 
techniques to visualise and further understand the intracellular mechanisms of action of external agents, both 44 
APIs and nanoparticles in cells. 45 
 46 
Keywords: nanomedicine, doxorubicin, chitosan nanoparticles, in vitro cytotoxicity, numerical simulations. 47 
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 56 
Introduction 57 
 58 
Encapsulation of active pharmaceutical ingredients (API) in nanoparticle delivery vehicles potentially enables: 59 
targeting of specific tissues or cells, release of the API in a controlled manner, and/or reduction of the necessary 60 
dose, thereby reducing potential side effects (e.g. toxicity) of the treatment [1,2]. The greater specific surface 61 
area of nanoparticles, due to reduced size, enables greater biological activity and reactivity, when compared to 62 
larger particles [3], and therefore the biocompatibility of the nanocarriers themselves must be assured and 63 
adequate toxicity studies must be performed, in vitro and in vivo. Furthermore, it is important to study the 64 
nanoparticle uptake and trafficking mechanisms as well as the drug release at cellular and subcellular level. In 65 
this context, the in vitro study using model loaded nanoparticle drug systems, and kinetic modelling of response 66 
can add much to the understanding of the drug delivery processes. 67 
Doxorubicin (DOX) is one of the most used chemotherapeutic agents for cancer treatment [4]. 68 
Nevertheless, problems related to resistance development [5], acute cardiotoxicity [6], low penetration and 69 
limited distribution in solid tumours [7], have led to investigations of alternative forms of administration. The 70 
majority of research has involved the association of doxorubicin to liposomes, exploring the interactions 71 
between lipid and drug charges [8]. However, indications of dermal and renal toxicity have been observed 72 
[9,10]. An alternative approach is to encapsulate doxorubicin within a positively charged nanocarrier, which 73 
would favour cellular adhesion and uptake, as cell membranes are negatively charged [11]. 74 
Chitosan (CS) is a linear cationic polysaccharide prepared through N-deacetylation of chitin. Generally 75 
recognised as safe, it has demonstrated biocompatible, non immunogenic, non toxic and biodegradable 76 
properties, and is thus a good candidate for pharmaceutical and biomedical applications [12,13]. In addition, 77 
considering intravenous administration, positively charged particles would interact with different blood 78 
components, which can favour different patterns of organ biodistribution and/or accumulation [14]. Chitosan 79 
nanoparticles can be formulated through several techniques, such as coacervation, co-precipitation, solvent 80 
evaporation, ionotropic gelation, and microemulsion, among others [11,15,16]. It should be noted that, although 81 
some regulatory definitions of nanoparticles restrict the term to a “particle with one or more dimensions of the 82 
order of 100 nm or less” [17], in other fields, such as Nanomedicine, the term is used to cover a broader size 83 
range and, for example, the International Standards Organisation Technical Committee on Nanotechnologies 84 
describes the “understanding and control of matter and processes at the nanoscale, typically, but not exclusively, 85 
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below 100 nanometers in one or more dimensions” [18] and it is in this context that the term nanoparticle is 86 
used in this work.  Ionotropic gelation allows the preparation of chitosan nanoparticles in aqueous solution and 87 
avoids the use of organic solvents, high energy conditions and extreme conditions. Janes et al. [14], have 88 
employed ionic bridging with the dextran sulphate polyanion and polymer/drug (DOX) complexation to 89 
improve the drug delivery profile in vitro, and demonstrated intracellular distribution of the drug after the 90 
endocytosis of the loaded nanoparticles. 91 
While the development of chitosan nanoparticles for administration of anticancer drugs and other 92 
substances is promising, the capacity to visualise the in situ behaviour of materials, particularly in the biological 93 
context, as well as characterise their interactions and toxicological effects, is of fundamental importance [19]. 94 
European Union directives [20] concerning substitution, reduction, and refinement of animal experimentation, 95 
prioritize the development of rapid and economically viable in vitro techniques for application in 96 
pharmaceutical and toxicological investigations. In vitro models are rapid, effective and usually well defined 97 
systems that can be used to evaluate several toxicological responses, establishing specific threshold of effects in 98 
cells and allowing studies of the structure-activity of nanomaterials [21]. Numerical simulations of nanoparticle 99 
uptake and cellular responses, based on rate equation models, have been demonstrated to extend the 100 
understanding which can be gleaned from conventional in vitro cytotoxicity assays, allowing a better 101 
conceptualisation of the underlying processes [22,23]. Thus, the aim of the present study was to investigate the 102 
intracellular delivery of the doxorubicin by loaded chitosan nanoparticles, as a model system, in an 103 
adenocarcinoma human alveolar basal epithelial cell line (A549) in vitro, through conventional cytotoxicity 104 
assays and fluorescence microscopy. The A549 cell line was chosen as clinical applications of DOX target solid 105 
tumors such as lung cancer, as well as for consistency with other studies [24-26, 41]. Adding to the study of 106 
Janes et al. [14], Numerical simulations of the toxic responses to the free drug, pristine and loaded nanoparticles 107 
are used to elucidate the underlying subcellular distribution and responses. 108 
 109 
Materials and Methods 110 
 111 
Materials 112 
 113 
Chitosan hydrochloride (CL113, 110 kDa, 86% deacetylation degree) was purchased from Pronova Biopolymer 114 
(Norway). Doxorubicin hydrochloride (DOX, 98.0-102.0%), sodium tripolyphosphate (TPP, 85.0%) and sodium 115 
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dodecyl sulphate (SDS, ≥99.0%) were obtained from Sigma-Aldrich. Reagents for Alamar Blue® and 3-[4,5-116 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assays, as well as cell culture media and 117 
supplements and trypsin solution were purchased from Biosciences (Ireland). Ultrapure water used for all 118 
experiments was obtained from a Milli-Q water purification system (Millipore Co., USA). 119 
 120 
Preparation of chitosan nanoparticles 121 
 122 
Chitosan nanoparticles (CS-TPP) were prepared by ionotropic gelation [15]. Pre-formulation studies were 123 
performed to obtain chitosan nanoparticles with adequate amounts of each component, according to the methods 124 
described previously [14,16], with some modifications. Briefly, 21 mg of CS were dissolved in 10 mL of 1% 125 
acetic acid (pH 4.8 adjusted with 2M NaOH solution) and 500 µL of this solution were mixed with 10 µL of 10 126 
mg/mL sodium dodecyl sulphate (SDS) and 10 µL of 10 mg/mL DOX solution (water was used for unloaded 127 
nanoparticles). 100 µL of a 2.9 mg/mL sodium tripolyphosphate (TPP) solution were added to the CS solution 128 
under magnetic stirring, leading to the immediate formation of the nanoparticles. The suspension formed was 129 
centrifuged at 1500 × g for 40 min for purification, the supernatant was discarded and the pellet re-suspended in 130 
water. The preparation process was performed inside a laminar flow hood. SDS was employed to counter-131 
balance the charges in the particle and enable doxorubicin (pKa = 8.2) to be encapsulated.  132 
 133 
Physicochemical characterisation of chitosan nanoparticles 134 
 135 
Number mean diameter and particle size distribution were evaluated by dynamic light scattering and zeta 136 
potential was determined by laser Doppler microelectrophoresis (Zetasizer
®
 Nano ZS, Malvern Instruments, 137 
UK). The system is routinely calibrated with NIST 3000 Series Nanosphere™ Size Standards, available from 138 
Thermo Scientific (60nm, 100nm and 1m). Particle concentration was analysed by turbidimetry [27]. 139 
The method for quantification of DOX encapsulation in the DOX-CS-TPP nanoparticles used in this 140 
work was UV spectrophotometry (SpectraMax
®
 M2, Molecular Devices, USA), as it is fast, precise and has 141 
good specificity [28]. 142 
 143 
Quantification of doxorubicin 144 
 145 
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Quantification of DOX was performed at 482 nm after validation of the analytical method by the determination 146 
of the following parameters: specificity, linearity, repeatability and accuracy. A standard solution of 10 mg/mL 147 
of DOX was used, from which calibration curves of absorbance at 482 nm were constructed over the DOX 148 
concentration range 34 – 311 µM (20 – 180 µg/mL). Encapsulation efficiency was calculated according to 149 
equation (S1), in which Total DOX is the absorbance of the suspensions of loaded nanoparticles before 150 
ultracentrifugation and Free DOX is the absorbance of the supernatant after ultracentrifugation of suspensions of 151 
loaded nanoparticles at 14000 × g for 10 min in centrifugal filter units (30K, Amicon
®
, EMD Millipore Co., 152 
MA, USA). The results are expressed as the mean of three different batches. 153 
 154 
Equation (S1)                                 
                
        
 155 
 156 
Cell culture 157 
 158 
The A549 human alveolar adenocarcinoma cell line was obtained from ATTC (Manassas, USA) and employed 159 
for cytotoxicity evaluations. Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) F-12, 160 
supplemented with 10% foetal bovine serum (FBS), 45 UI/mL penicillin and 45 µg/mL streptomycin, and kept 161 
in humidified incubator at 37 °C (5% CO2). 162 
 163 
Cytotoxicity studies 164 
 165 
Cells were seeded in 96-well plates at densities of 1 × 10
5
, 7 × 10
4
 and 3 × 10
4
 cells/mL for 24, 48 and 72h of 166 
exposure, respectively. Cells were allowed to attach for 24h and then washed with phosphate buffered saline 167 
(PBS) prior to treatment with fresh medium containing unloaded chitosan nanoparticles (CS-TPP), solutions of 168 
doxorubicin in water (free DOX) or doxorubicin-loaded chitosan nanoparticles (DOX-CS-TPP) in the 169 
concentration range 1.5 × 10
-4
 – 7.6 µM (8.8 × 10-5 – 4.4 µg/mL) of DOX. CS-TPP results are expressed in 170 
particles/mL (1 × 10
7
 – 5 × 1011 particles/mL, as calculated by turbidimetry). After the requisite exposure time, 171 
cell viability was measured by MTT and AB assays in accordance with manufacturer’s instructions.  172 
 173 
Live cell imaging 174 
 175 
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Fluorescence microscopy 176 
 177 
A549 cells were seeded in glass bottom Petri dishes at a density of 1 × 10
4
 cells/dish in DMEM F-12 medium 178 
supplemented with 10% FBS, and kept in a humidified incubator at 37 °C (5% CO2). Cells were allowed to 179 
attach for 24h, washed with PBS and exposed to 7.6 µM (4.4 µg/mL) of free DOX or 5 × 10
11
 particles/mL of 180 
CS-TPP and DOX-CS-TPP (as calculated by turbidimetry) or fresh medium as a negative control, and incubated 181 
for 24h. After the requisite exposure time, cells were washed three times with pre-warmed PBS (37 °C). 182 
Hoechst 33342 stain solution (initial concentration of 20 mM), used for DNA and nucleus staining of eukaryotic 183 
cells, was diluted 2000 times in PBS and cells were stained for 10 min. Before imaging, cells were washed three 184 
times with PBS to assure complete removal of non-internalised stain. Images were obtained through the 185 
software AxioVision (version 4.8.1.0, Carl Zeiss Imaging Solutions Gmbh, Germany), annexed to an inverted 186 
microscope for transmitted light and epifluorescence Axiovert 200M (Carl Zeiss, Germany), equipped with 187 
AxioCamHR camera. Brightfield settings with 63x objective, as well as DAPI (blue) and DsRed (red) filters 188 
were used for imaging. 189 
 190 
Confocal microscopy 191 
 192 
A549 cells were seeded in glass bottom Petri dishes at a density of 1 × 10
4
 cells/dish in DMEM F-12 medium 193 
supplemented with 10% FBS, and kept in a humidified incubator at 37 °C (5% CO2). Cells were allowed to 194 
attach for 24h, washed with PBS and subjected to early endosomal staining (Cell Light Early Endosomes-RFP, 195 
BacMam 2.0, 30 ppc) for 16h. After this period, cells were exposed to 7.6 µM (4.4 µg/mL) of free DOX or 5 × 196 
10
11
 particles/mL of CS-TPP and DOX-CS-TPP (as calculated by turbidimetry) or fresh medium as negative 197 
control, and incubated for 4h. After exposure for the appropriate time, cells were washed three times with pre-198 
warmed PBS (37 °C), to ensure complete removal of non-internalised stain. Images were obtained through 199 
confocal fluorescence microscope LSM 510 META (version 3.2 SP2, Carl Zeiss, Germany), using fixed 200 
excitation wavelength at 488 nm and fluorescence detection was achieved with a 505-530 nm band pass filter 201 
(green) and a 585 nm long pass filter (red). 202 
 203 
Statistical analyses 204 
 205 
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All experiments were carried out in triplicate (three independent experiments). MTT and AB assays results are 206 
expressed as mean percentage relative to unexposed control ± standard deviation (SD), wherein unexposed 207 
control values were considered 100%. Differences among groups were statistically analysed through the 208 
software GraphPad Prism (version 5.0, GraphPad Software, Inc., USA), and a p-value < 0.05 was considered 209 
significant. Data normality was confirmed by the Kolmogorov-Smirnov test and the homogeneity of variances 210 
was evaluated using the Bartlett test. One-way ANOVA followed by Bonferroni’s post-test was employed for 211 
data with normal distribution and homogeneous variances. Non-parametric Kruskal-Wallis test followed by 212 
Dunn’s post-test was applied to samples without normal distribution and/or inhomogeneous variances. 213 
Cytotoxicity data were adjusted to a sigmoidal curve through the software SigmaPlot™ (version 10.0, Systat 214 
Software, Inc., USA) and a four-parameter model (Eq. 1) was used to calculate the effective nanomaterial 215 
concentration that caused 50% of the maximum observed inhibition compared to unexposed controls (EC50).  216 
Equation (1)          
       
   
 
    
          
 217 
Numerical simulations were performed by integration using the iterative Euler approach [29] and SigmaPlot™ 218 
(v.10.0) was used to generate the values and graphs. 219 
 220 
Results 221 
 222 
Preparation and physicochemical characterisation of chitosan nanoparticles 223 
 224 
The characterisation results for size distribution, surface charge and particle concentration of chitosan 225 
nanoparticle suspensions are listed in Table 1. The number size distribution of unloaded (CS-TPP) and 226 
doxorubicin-loaded (DOX-CS-TPP) nanoparticles is illustrated in Online Resource 1 (Figure S1). 227 
In order to quantify the encapsulation of DOX, calibration curves were constructed by plotting absorbance 228 
versus DOX concentration over the range 34 – 311 µM. The least squares method was applied for linear 229 
regression analysis and the calculated value for the correlation coefficient (r
2
 = 0.9996) showed excellent 230 
linearity of the calibration curve, with no significant deviation from linearity. The specificity was determined by 231 
the absorption spectrum of CS-TPP formulations, in comparison with the absorption spectra of free DOX and 232 
DOX added to CS-TPP (Online Resource 1, Figure S2). The absorbance of CS-TPP was determined to be 233 
0.0128 at 482 nm, thus achieving good selectivity towards DOX, without any potential interference from the 234 
formulation. 235 
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Repeatability (inter-day precision) was studied by calculating the relative standard deviation (RSD) for 236 
three independent determinations of three different concentrations, from which a value of RSD < 5% was 237 
obtained. In addition, the accuracy of the analytical method, which is the closeness of the test results obtained 238 
by the method to the true value, was calculated by three replicate determinations of concentrations of 34, 145 239 
and 256 µM in the presence of CS-TPP. The results showed that the proposed method has an accuracy of 103.9 240 
± 2.0% within the desired range.  241 
In this way, the DOX concentration in DOX-CS-TPP formulations was determined to be 76 ± 7 µM by 242 
direct absorbance determination, and the encapsulation efficiency after purification was 95 ± 1%, according to 243 
absorbance determination of the supernatant. Thus, a DOX-CS-TPP concentration of 1 particle/mL corresponds 244 
to a dose of 8.29 ± 0.92 × 10
-12
 M. 245 
 246 
Cytotoxicity studies 247 
 248 
Figure 1 illustrates the dose dependent cytotoxic responses for both MTT and AB at 24, 48 and 72h. For both 249 
assays, a significant dose dependent response is observed, the loss of viability increasing with increasing dose 250 
and exposure time. Notably, the MTT is somewhat more responsive to the DOX exposure, particularly at shorter 251 
exposure times. For the case of CS-TPP nanoparticles, a significant toxic response is also observed (40.6 ± 4.2% 252 
and 77.0 ± 9.0% viability, MTT and AB respectively, at 5 × 10
11
 particles/mL at 48h), although for equivalent 253 
exposure times, the response for both assays is considerably lower over the exposure range, compared to the 254 
free DOX exposure range (Figure 1A and B). As is the case for free DOX, MTT is seen to be a more sensitive 255 
assay than AB (Figure 1C and D) (EC50 of 0.38 ± 0.08 and 0.93 ± 0.29 µM of DOX for MTT and AB, 256 
respectively, at 24h). When exposed to DOX loaded chitosan nanoparticles, DOX-CS-TPP (Figure 1E and F), 257 
over the same nanoparticle exposure dose range, a stronger toxic response (difference Max – Min viability of 258 
111.8 and 109.7 for MTT and AB, respectively, at 72h) is elicited than for unloaded CS-TPP nanoparticles 259 
(difference Max – Min viability of 64.2 and 10.8 for MTT and AB, respectively, at 72h), indicating some degree 260 
of success in the intracellular delivery of the chemotherapeutic agent encapsulated as cargo in the nano drug 261 
delivery vehicle. Over the same equivalent DOX dose range, however, the toxic response appears weaker, at 262 
least at the shorter exposure time of 24h (at the higher dose, DOX elicits 35.0 ± 14.4% and 55.8 ± 16.3% 263 
viability, while DOX-CS-TPP elicits 48.1 ± 6.6% and 81.6 ± 6.0% viability, for MTT and AB, respectively), 264 
indicating a reduced intracellular rate of delivery of DOX. 265 
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The lines of Figure 1 show fits of equation 1 to the respective experimental data. The associated fit 266 
parameters are tabulated in Table S1 (Online Resource 1). In general, a trend of decreasing EC50 with increasing 267 
exposure time reflects the increasing toxic response, and the relatively lower values for MTT compared to AB 268 
for each exposure time reflects the higher sensitivity of that assay. Of particular relevance is the comparison of 269 
the EC50 values for free DOX exposure compared to the equivalent DOX values for the DOX-CS-TPP 270 
exposures, which, for both MTT and AB, reveal a considerably higher EC50 dose equivalent for the latter (AB 271 
EC50 of 0.26 ± 0.06 and 0.07 ± 0.02 µM of DOX for DOX-CS-TPP and free DOX, respectively, at 72h).  272 
 273 
Live cell imaging 274 
 275 
Firstly, cells were observed using fluorescent microscopy, after incubation for 24h with test suspensions and the 276 
Hoechst 33342 blue stain for the nucleus. Red fluorescence imaging was used to visualize DOX. Figure 2 shows 277 
that the red fluorescence in the cells exposed to free DOX is concentrated in the nucleus. In comparison, cells 278 
exposed to DOX-CS-TPP show less co-localization of the red fluorescence with the nuclear stain.  279 
Subsequently, A549 cells were incubated for 4h with CS-TPP, free DOX or DOX-CS-TPP to further 280 
investigate the cellular uptake behavior by confocal laser scanning microscopy (CLSM), after early endosomal 281 
staining. As shown in Figure 3, the green fluorescence of the endosomal stain was observed in all the cells, 282 
independent of the treatment, showing successful staining of early endosomes. After exposure to unloaded CS-283 
TPP nanoparticles, the endosomal staining is concentrated in small vesicles, distributed throughout the 284 
cytoplasm, consistent with uptake of the nanoparticles into early endosomes [30]. Furthermore, the intracellular 285 
DOX can be identified by the red fluorescence, which is observed predominantly in the nuclei for free DOX 286 
treated cells. For DOX-CS-TPP treated cells, DOX fluorescence is also present in the cytoplasm, corroborating 287 
the fluorescence microscopy images, and indicates its localization in early endosomes (yellowish color), as well 288 
as in other subcellular compartments.  289 
 290 
Numerical simulations using rate equation model 291 
 292 
The cellular uptake of, and responses to, the external agents can be numerically simulated in order to further 293 
elucidate the different responses. Such an approach, based on a rate equation model, has previously been 294 
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employed to simulate the time and dose dependent cytotoxicity of polymeric dendrimer nanoparticles, as well as 295 
the observed differences in responses for different cytotoxic assays and cell lines [23,31]. 296 
In a similar fashion, for a dose D, the uptake of DOX within the cells can be described by the first 297 
order rate equation:  298 
Equation (2)    
     
  
                299 
where NDOX is the dose of internalised DOX and kDOX is the rate of internalisation. The term (D-NDOX) allows 300 
for depletion of the applied dose by the uptake process. The accepted mode of action of DOX, once internalised, 301 
is the rapid localisation in the nucleus, in which it intercalates with DNA, resulting in the onset of apoptosis 302 
[32]. In the formalism of Black and Leff  [33], the DOX binds with receptors, according to the equation:  303 
Equation (3)    
    
  
                      304 
where NRB is the number of bound receptors, kRB is the receptor binding rate, and NRmax is the maximum number 305 
of available receptors. The MTT assay reveals changes in mitochondrial activity, which, as a result of the action 306 
of DOX in the nucleus and the onset of apoptosis, can be modelled according to:  307 
Equation (4)    
    
  
                      308 
where MTT is the response of the assay as a function of time, MTTmax being the maximum at zero exposure, 309 
and kMTT is the rate of response of the mitochondria as a result of the nuclear insult of DOX.  310 
Equations (2-4) can be solved numerically, generating a time dependence of the cellular uptake of and 311 
response to DOX exposure, over the dose range. Figures 4A and B show the simulated dose dependent response 312 
for the time points of 24, 48 and 72 hrs, as compared to the experimentally determined responses of Figure 1. A 313 
list of fit parameters is provided in the Online Resource 1. As shown in Figure 4C, for 0.1 M dose, a rapid 314 
uptake of DOX and binding to the nuclear receptors is followed by a slower response of the mitochondrial 315 
activity. The dose dependent responses at the experimentally measured time points are well reproduced by the 316 
simulation based on the rate equation model. 317 
For the case of the AB response, the experimental results are not well simulated by either a cascade of 318 
AB response, triggered by the MTT response of Equation 4, or even the AB response triggered by the nuclear 319 
receptor binding described by Equation 3. Instead, the closest simulation of the experimental observations was 320 
achieved by providing an alternative route of intracellular interaction of the internalised DOX molecules. In 321 
addition to the mode of action of DNA intercalation, internalised DOX can also lead to the generation of free 322 
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radicals, resulting in DNA and cell membrane damage [34]. The response can be simulated such that, after 323 
uptake according to Equation 2, the DOX interacts according to:  324 
Equation (5)    
    
  
         
                 325 
where NFR is the number of generated free radicals, kFR is the radical generation rate, and NFRmax is the 326 
maximum number of free radicals which can be generated. The square root dependence on NDOX is indicative of 327 
a cascade process of one DOX molecule resulting in two or more radicals. The AB assay registers changes in 328 
cytoplasmic activity, which, as a result of the action of DOX in the cytoplasm, can be modelled according to:  329 
Equation (6)    
   
  
                    330 
where AB is the response of the assay as a function of time, ABmax being the maximum at zero exposure, and 331 
kAB is the rate of response of the cytoplasmic activity as a result of the insult of DOX. Figure 5B shows the 332 
simulated AB response to the DOX exposure, compared to the experimentally observed responses. As shown in 333 
Figure 4C, the AB response (at a dose of 0.1 M) is slower than that of the MTT, resulting in lower cytotoxic 334 
responses at the respective time and dose points.  335 
The uptake of, and cellular cytotoxic response to, CS-TPP nanoparticle exposure, as a function of time 336 
and dose, can similarly be simulated. For a dose D, the uptake of CS-TPP within the cells can be described by 337 
the first order rate equation:  338 
Equation (7)    
    
  
              339 
where NNP is the dose of internalised CS-TPP nanoparticles and kNP is the rate of internalisation. The term (D-340 
NNP) allows for depletion of the applied dose by the uptake process. As shown in Figure 3, using CLSM, the 341 
nanoparticles are endocytosed and the common mechanism of toxicity is further trafficking through lysosomes 342 
and the generation of oxidative stress, resulting in cell damage and apoptosis [35]. Following the approach of 343 
Maher et al. [23], the cellular response is the result of an interaction of the endocytosed nanoparticles with an 344 
intracellular source of reactive oxygen species (ROS), Nsource, which is depleted by the ROS generation process. 345 
Thus,  346 
Equation (8)    
        
  
                   347 
where kA is the interaction rate for the nanoparticles and source, and A is an empirical constant.  The generation 348 
of ROS is then described by:  349 
Equation (9)    
     
  
                                 350 
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The second term of Equation (9) describes the quenching of the ROS at a rate kq, and depends on both; ROS 351 
levels, NROS, and antioxidant levels, NGSH (NGSH(0) = 0). In the study by Mukerjee and Byrne [31], the 352 
antioxidant levels were represented by the experimentally measured values of glutathione (GSH)
 
which are 353 
represented by:  354 
Equation (10)    
     
  
                          355 
For both MTT and AB, the loss of viability is represented by equations (4) and (6), replacing NRB or 356 
NFR by NROS and nanoparticle specific rate constants k’MTT and k’AB. The resultant simulated plots of dose 357 
dependent viability for the time points of 24, 48 and 72 hrs are shown in Figure 5 (A) MTT, and (B) AB. The fit 358 
parameters are provided in the Online Resource 1. The simulations satisfactorily reproduce the trends observed 359 
experimentally. A notable difference between the simulations for DOX and CS-TPP is the rate of uptake of the 360 
respective agent by the cells, as shown in Figure 5C, which is substantially slower for the nanoparticles than for 361 
the molecular species, (kDOX= 2 hr
-1
, kNP = 0.5 hr
-1
) consistent with the observations of Salvati et al. [30] for 362 
polystyrene nanoparticles uptake compared to free organic fluorescent dye molecules.  363 
To simulate the cytotoxic responses to the nanoparticle encapsulated DOX, the DOX-CS-TPP uptake 364 
was simulated according to Equation (7), and subsequent responses to the endocytosed nanoparticles were 365 
evaluated according to Equations (8-10), in all cases using the same fit parameters as for CS-TPP (Online 366 
Resource 1). As shown in Figure 3, however, once endocytosed, the DOX-CS-TPP release the DOX into the 367 
cytosol, from where it reaches the nucleus. The process is simulated according to the equation:  368 
Equation (11)    
     
  
          369 
where kR denotes the rate of release of DOX from the endosomes. The value of kR incorporates the scaling 370 
factor of the encapsulation efficiency. The released DOX can then interact with the cell, as described by 371 
Equations (3-6). In a simple approximation, the combined effect of the CS-TPP nanoparticles and the released 372 
DOX can be taken to be a linear combination, such that the viability of the cell, as measured by the MTT and 373 
AB assays, respectively, can be represented by:  374 
Equation (12)    
    
  
                                     375 
Equation (13)    
   
  
                    
 
          376 
For both MTT and AB, k and k’ indicate the rates of the two independent routes towards cell death, elicited by 377 
the DOX and CS-TPP nanoparticles respectively. The simulations of Figure 6 provide a reasonable reproduction 378 
of the experimental observations for the MTT and AB responses at 24, 48 and 72 hrs, although deviations may 379 
14 
 
be an indication of a more complex release process of DOX from the CS-TPP nanoparticles, and subsequently 380 
from the endosomes, or a co-operative or even competing effect of the two toxicants.  381 
Figure 7 provides a visualisation of the time dependence of the DOX-CS-TPP nanoparticle uptake and 382 
different cellular responses. It is clear that, for both MTT and AB, the loss of viability due to the toxic response 383 
to the nanoparticles is substantial (NP Response), although more significantly so for MTT than for AB. Notably, 384 
the DOX response, for both assays is delayed significantly compared to the response to the free DOX (Figure 385 
4C), due to the delayed release of the API from the nanoparticles, encapsulated within the intracellular 386 
endosomes/lysosomes.  387 
 388 
Discussion 389 
 390 
In the present work, chitosan (CS) was ionically cross-linked with the counter-ion sodium tripolyphosphate 391 
(TPP) through ionotropic gelation, in which positive and negative groups of each component interact to form 392 
hydrogel nanoparticles [15]. The results show that, for both CS-TPP and DOX-CS-TPP nanoparticles, 393 
monomodal and nanometric distributions (220 – 1106 nm) were obtained. Zeta potential values demonstrate the 394 
positive characteristic of the particle surface charge, even in the presence of SDS. Furthermore, suspensions 395 
presented adequate polydispersity index and particle concentration for nanoscale formulations [27]. Besides, the 396 
overall results of the determination of validation parameters analysed demonstrated the adequacy of the 397 
proposed method for quantification of DOX [36]. 398 
The synthesized chitosan nanoparticles loaded with the API doxorubicin were used in this study to 399 
elucidate the cytotoxicity and internalization profiles in A549 cells. A variety of endpoints are commonly used 400 
to evaluate cytotoxic responses of cell lines in vitro. Each cytotoxicity assay measures a different response or 401 
adjacent cell function. The Alamar Blue
®
 assay is based on fluorescence, which indicates the innate cellular 402 
metabolic activity by the conversion of resazurin (non fluorescent) in resorufin (fluorescent) [37], while the 403 
MTT assay indicates mainly mitochondrial metabolism [38]. The in vitro toxicity is expressed as the effective 404 
concentration for reduction of 50% of cell viability (EC50), which is essentially the midway concentration 405 
between minimum and maximum responses. The EC50 values for A549 cells found in this work for free DOX 406 
are comparable with other studies [39-41], ranging from 0.5 to 5 μM. Notably, however, unless minimum and 407 
maximum responses are close for different test substances/formulations, EC50 values are difficult to compare 408 
among the variety of cell lines, assays employed and nanoparticle characteristics [22,23].  409 
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In order to further understand the differences in cytotoxic responses to the free API and the API loaded 410 
in the nanoparticles, it is necessary to image the localization of the drug within the cells. Live cell imaging was 411 
carried out following 4h or 24h exposure to CS-TPP, free DOX or DOX-CS-TPP, or fresh medium as negative 412 
control. The fluorescence microscopy observations indicate that DOX localizes in the nucleus to a greater extent 413 
when in free form compared to the DOX confined in nanoparticles, which may imply that the internalization 414 
process of nanoparticles, when compared to the free drug, occurs through a different and/or slower mechanism. 415 
However, due to limited resolution of this technique, it was not entirely clear whether the nanoparticles released 416 
DOX on the surface of the cells or whether they were internalized into the cells.  417 
In this way, we performed confocal laser scanning microscopy (CLSM) in order to better visualize the 418 
DOX localization within the cells. Our results clearly indicate that DOX-CS-TPP nanoparticles are taken up by 419 
the cell mostly through endocytosis and DOX is released to the nucleus afterwards, in contrast to free DOX, 420 
which is transported into cells via passive diffusion [41,42] after which it is rapidly localized within the nucleus. 421 
Different cell uptake mechanisms of free drugs and drug-loaded nanoparticles are widely described in 422 
scientific literature [43-45]. In particular, doxorubicin is useful for these studies due to its pronounced red 423 
fluorescence. It is hypothesized that the acidic environment of endosomal/lysosomal compartments helps the 424 
release of DOX from nanoparticles, reaching the nucleus thereafter [45]. The delayed release of DOX, reducing 425 
the overall cytotoxicity, might be beneficial depending on the ultimate effect in the cell. In order to elucidate 426 
these potentially different underlying subcellular responses, numerical simulations from cytotoxicity assays data 427 
were performed. 428 
Numerical simulations, based on a rate equation model to describe the uptake and distribution of the 429 
free DOX, nanoparticles and DOX loaded nanoparticles within the cells, and the subsequent dose and time 430 
dependent cytotoxic responses, are used to further elucidate the API distribution processes. The study 431 
demonstrates that encapsulation of the API in nanoparticles results in a delayed release of the drug to the cell, 432 
resulting in a delayed cellular response. Moreover, unloaded nanoparticles also displayed a degree of toxicity 433 
that may indicate that DOX-CS-TPP cytotoxicity occurs through different cell death mechanisms, which in turn 434 
can potentiate the cellular responses. These have been independently modelled for the free DOX and pristine 435 
CS-TPP nanoparticles, and the mechanisms combined in the model for the DOX-CS-TPP toxic response for 436 
both assays. As discussed in the introduction, encapsulation of APIs in nanoparticle delivery vehicles has 437 
several potential advantages for clinical treatments: the passive targeting of specific tissues or cells, release of 438 
the API in a controlled manner, reduction of the necessary dose and/or number of administrations, thereby 439 
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reducing potential side effects, ultimately improving efficacy and patient compliance [2,46]. The cellular 440 
internalization of chitosan nanoparticles and the retention of encapsulated DOX bioactivity have been 441 
demonstrated [11,14]. However, no previous reports have investigated unloaded and DOX-loaded chitosan 442 
nanoparticles of approximately 500 nm in such depth. This study demonstrates that DOX encapsulated within 443 
chitosan nanoparticles, although they are engulfed in endosomal vesicles, remains bioavailable and elicits a 444 
toxic response in the cells, in vitro, in a similar fashion to the free API. Endoscytosis of the nanoparticles 445 
containing API results, however, in a delayed release of the drug to the cell, resulting in a delayed cellular 446 
response which could be potentially further controlled by tailoring the physicochemical properties of the 447 
nanoparticle.  448 
In summary, unloaded and doxorubicin-loaded chitosan nanoparticles were successfully synthesized 449 
and physicochemically characterized for further use in in vitro experiments. This work sheds new light on the 450 
differences of cellular internalization of free or encapsulated APIs, the latter having a delayed response. 451 
Although free doxorubicin elicited a stronger response in comparison to doxorubicin-loaded chitosan 452 
nanoparticles, such a delayed release of the drug from the nanoparticles to the cell. This effect results in similar 453 
in vitro efficacy in the time frame of the cytotoxicity experiment, but may have different implications in an in 454 
vivo system. For example, it may overcome partially or completely the development of tumour resistance during 455 
chemotherapy, or it may show a better selectivity towards cancerous cells in comparison to non-cancerous cells. 456 
These hypotheses should be addressed in future studies. We further demonstrated the potential of mathematical 457 
modelling to visualise and better understand the intracellular mechanisms of action of external agents, both APIs 458 
and nanoparticles in cells. DOX itself is a well-known anticancer agent that triggers tumor resistance and 459 
cardiotoxicity during chemotherapy. Its selectivity towards carcinogenic and non-carcinogenic cells is low [39], 460 
however, and ultimately, improved selectivity of nanoformulations, potentially by adding additional cell 461 
targeting functionalities [47,48], should be demonstrated. DOX is usually administered intravenously, but 462 
nanoparticles can be administered intravenously or through the pulmonary route in liquid or powder form. 463 
Although, a full study of the metabolisation of DOX and of the stability of the nanoparticles, administered 464 
according to established clinical protocols is beyond the scope of the present work, comparative in vitro/in vivo 465 
studies must be conducted in order to fully demonstrate mathematical modelling as a viable alternative to the 466 
experimentally testing of nanoparticles. 467 
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Tables 599 
Table 1. Results of physicochemical characterisation of chitosan nanoparticles. 600 
Parameter
a
 CS-TPP DOX-CS-TPP 
Number mean (nm) 509 ± 13 473 ± 41 
Polydispersity index 0.28 ± 0.05 0.31 ± 0.2 
Zeta potential (mV) 35 ± 4 34 ± 4 
Particle concentration (particles/mL) 3.7 ± 0.2 × 10
12
 5.1 ± 0.2 × 10
12
 
a 
Results are expressed as mean ± SD. 601 
 602 
Figure Legends 603 
Fig. 1 Experimental (symbols) and simulated (lines) exposure time and dose dependent viability, as measured 604 
using the MTT and Alamar Blue
®
 (AB) assays, for A549 cells at 24, 48 and 72h. For (E) and (F) the x-axis label 605 
indicates the dose µM and particles per mL. Viability is expressed as the mean ± S.D. of the % decrease in 606 
formazan absorbance (for MTT) or resorufin fluorescence (for Alamar Blue
®
), as compared to the unexposed 607 
control of three independent experiments. (A) and (B) MTT and AB of CS-TPP; (C) and (D) MTT and AB of 608 
Free DOX; (E) and (F) MTT and AB of DOX-CS-TPP 609 
Fig. 2 Fluorescence microscopy images of A549 cells after incubation with CS-TPP, free DOX or DOX-CS-610 
TPP for 24h. The arrows highlight the co-localization of red fluorescence from DOX with blue nuclear stain 611 
(pinkish color) in Free DOX treated cells and predominantly less co-localization in DOX-CS-TPP treated cells 612 
Fig. 3 Confocal microscopy images of A549 cells after incubation with CS-TPP, free DOX or DOX-CS-TPP for 613 
4h. The arrows highlight the co-localization of DOX-CS-TPP with early endosomes (yellowish color) 614 
Fig. 4 Simulated dose dependent cytotoxic responses for exposure to free DOX (A) MTT and (B) AB. (C) 615 
Simulated time dependent DOX uptake and cytotoxic responses of MTT and AB at a dose of 0.1 M 616 
Fig. 5 Simulated dose dependent cytotoxic responses for exposure to CS-TPP (A) MTT (B) AB. (C) Simulated 617 
time dependent CS-TPP nanoparticle uptake and cytotoxic responses of MTT and AB at a dose of 10
10
 618 
particles/mL 619 
Fig. 6 Simulated dose dependent cytotoxic responses for exposure to DOX-CS-TPP (A) MTT (B) AB. 620 
Simulated time dependent DOX-CS-TPP uptake and cytotoxic responses of (C) MTT and (D) AB at a dose of 621 
10
10
 particles/mL (0.1µM of DOX) 622 
 623 
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Figure 5 659 
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